In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Skye Bioscience Inc (NASDAQ: SKYE) was $1.66 for the day, down -12.63% from the previous closing price of $1.9. In other words, the price has decreased by -$12.63 from its previous closing price. On the day, 6.73 million shares were traded. SKYE stock price reached its highest trading level at $2.0999 during the session, while it also had its lowest trading level at $1.65.
Ratios:
Our analysis of SKYE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.09 and its Current Ratio is at 6.09. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On October 06, 2025, Cantor Fitzgerald Downgraded its rating to Neutral which previously was Overweight but kept the price unchanged to $2.
On August 15, 2025, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $10.Evercore ISI initiated its Outperform rating on August 15, 2025, with a $10 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 22 ’25 when Schwab Andrew J. sold 170,449 shares for $3.42 per share. The transaction valued at 582,936 led to the insider holds 57,493 shares of the business.
Schwab Andrew J. sold 60,956 shares of SKYE for $217,613 on Aug 21 ’25. The Director now owns 63,963 shares after completing the transaction at $3.57 per share. On Aug 22 ’25, another insider, 5AM Partners VII, LLC, who serves as the 10% Owner of the company, sold 170,449 shares for $3.42 each. As a result, the insider received 582,936 and left with 57,493 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SKYE now has a Market Capitalization of 58877996 and an Enterprise Value of 3223034.
Stock Price History:
The Beta on a monthly basis for SKYE is 2.35, which has changed by -0.5561497 over the last 52 weeks, in comparison to a change of 0.15927899 over the same period for the S&P500. Over the past 52 weeks, SKYE has reached a high of $5.96, while it has fallen to a 52-week low of $1.14. The 50-Day Moving Average of the stock is -54.59%, while the 200-Day Moving Average is calculated to be -42.27%.
Shares Statistics:
SKYE traded an average of 631.26K shares per day over the past three months and 2678140 shares per day over the past ten days. A total of 30.99M shares are outstanding, with a floating share count of 18.10M. Insiders hold about 41.59% of the company’s shares, while institutions hold 27.40% stake in the company. Shares short for SKYE as of 1757894400 were 2745750 with a Short Ratio of 4.35, compared to 1755216000 on 2669234. Therefore, it implies a Short% of Shares Outstanding of 2745750 and a Short% of Float of 13.309999999999999.
Earnings Estimates
The stock of Skye Bioscience Inc (SKYE) is currently in the spotlight, with 6.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.35, with high estimates of -$0.3 and low estimates of -$0.44.
Analysts are recommending an EPS of between -$1.29 and -$1.61 for the fiscal current year, implying an average EPS of -$1.4. EPS for the following year is -$1.41, with 7.0 analysts recommending between -$0.71 and -$1.84.
